The Apex Times
Above the Noise
Business Wire
BusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex TimesBusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex TimesBusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex TimesBusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex Times
Back to front
Certara plugs NVIDIA BioNeMo agent toolkit into drug-development platform, aiming to speed discovery and regulatory work
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 7, 8:16 AM EDT

Certara plugs NVIDIA BioNeMo agent toolkit into drug-development platform, aiming to speed discovery and regulatory work

The Radnor, Pennsylvania company said it is integrating the NVIDIA BioNeMo Agent Toolkit into its AI platform so “life sciences agents” can help generate specialized insights across dosing, trial simulation, ADMET assessment, and regulatory evidence.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Certara said it has teamed with NVIDIA to expand its AI platform with the NVIDIA BioNeMo Agent Toolkit, adding what the companies describe as autonomous “life sciences agents” aimed at accelerating drug discovery and development. The integration is intended to connect Certara’s biosimulation software, proprietary datasets, and scientific know-how with AI-driven agents that can produce specialized, domain-focused outputs across multiple stages of the drug lifecycle.

In the announcement, Certara framed the agents as systems that can reason over scientific and clinical inputs, then help optimize dosing assumptions, simulate clinical trials, and evaluate ADMET properties, a standard set of pharmacology and safety-related measures that include absorption, distribution, metabolism, excretion, and toxicity. The company said the agents can also support the preparation of “regulatory-ready evidence,” while maintaining a human-in-the-loop design so scientists remain in control of key decisions.

Certara’s approach centers on its open integrated AI platform, which it said is built to unify tools and data rather than treat AI as a bolt-on. By wiring the BioNeMo Agent Toolkit into that platform, Certara is effectively extending its existing computational and biosimulation work with agentic workflows designed for specific scientific tasks.

The partnership also reflects a broader push in life sciences toward agent-driven automation. NVIDIA has previously described BioNeMo Agent Toolkit as a way to give AI agents domain-specific tools and skills for scientific discovery, positioning the software as part of an emerging “agentic life sciences” stack rather than a single model or one-off analysis feature.

The market response to the news was modest but positive. Following the announcement, Certara shares were reported to have gained about 2.38% in the next-day window tracked by one market-data provider, with data described as delayed and not necessarily attributable solely to the partnership.

For NVIDIA, the deal is another example of how it is trying to translate its AI software ecosystem into vertical, application-specific platforms. For Certara, it is a announcement that the company wants its simulation and regulatory workflow capabilities to pair more tightly with AI agents that can help generate work product faster, while still routing critical judgments through researchers.

Certara did not provide detailed information in the public reporting about deployment scope, such as whether customers will access the new agent capabilities immediately, how pricing will be handled, or what specific tools within its portfolio will be connected first. The company also did not disclose performance benchmarks, timelines for commercialization, or whether any particular regulatory pathway has been validated through the agent-assisted workflow.

Investors and customers will likely focus next on adoption, including which parts of the drug-development workflow see the fastest use, whether the agents reduce turnaround time in internal studies, and whether Certara can demonstrate that agent-generated regulatory evidence meets the same standards scientists would otherwise assemble manually. Any follow-on updates that include case studies, customer names (if permitted), or quantitative results would help clarify how much acceleration the new capability delivers in practice.

Why It Matters

  • Agentic AI is moving from general-purpose tools toward domain-specific workflows in life sciences, where regulators, safety testing, and trial design require specialized reasoning.
  • If Certara’s approach holds up, agents could reduce cycle times for simulation-heavy steps such as dosing strategy and trial planning, areas where computational work is often iterative.
  • The mention of “regulatory-ready evidence” underscores that the value proposition is not only speed but also defensibility, which is crucial for drug development teams.
  • For NVIDIA, the collaboration adds another concrete example of BioNeMo being packaged into partner platforms rather than remaining purely research-oriented.

Sources

Key Facts

  • Certara said it is integrating NVIDIA’s BioNeMo Agent Toolkit into its open integrated AI platform for drug discovery and development.
  • The companies described the upgrade as adding “life sciences agents” that can generate specialized insights across dosing, trial simulation, and ADMET assessment.
  • Certara said the agent outputs are intended to support the preparation of regulatory-ready evidence, while keeping scientists in the decision-making loop.
  • The announcement ties agent capabilities to Certara’s biosimulation software, proprietary datasets, and scientific expertise.
  • Market reporting following the news indicated Certara shares rose about 2.38% in the next-day period tracked by one data provider (with delayed data and attribution limitations noted).

Technology Related

Oct 18, 6:12 PM EDT
The Apex Times

Wall Street looks to earnings as AI worries pressure megacap tech

Equity index futures rose after sharp selling tied to fresh concerns about the durability of the artificial-intelligence trade, with traders pointing to upcoming results from Meta and other major technology names.

Wall Street looks to earnings as AI worries pressure megacap tech
The Apex Times
Certara plugs NVIDIA BioNeMo agent toolkit into drug-development platform, aiming to speed discovery and regulatory work | The Apex Times